Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19

Front Immunol. 2021 Oct 28:12:738093. doi: 10.3389/fimmu.2021.738093. eCollection 2021.

Abstract

Disease caused by SARS-CoV-2 coronavirus (COVID-19) led to significant morbidity and mortality worldwide. A systemic hyper-inflammation characterizes severe COVID-19 disease, often associated with acute respiratory distress syndrome (ARDS). Blood biomarkers capable of risk stratification are of great importance in effective triage and critical care of severe COVID-19 patients. Flow cytometry and next-generation sequencing were done on peripheral blood cells and urokinase-type plasminogen activator receptor (suPAR), and cytokines were measured from and mass spectrometry-based proteomics was done on plasma samples from an Indian cohort of COVID-19 patients. Publicly available single-cell RNA sequencing data were analyzed for validation of primary data. Statistical analyses were performed to validate risk stratification. We report here higher plasma abundance of suPAR, expressed by an abnormally expanded myeloid cell population, in severe COVID-19 patients with ARDS. The plasma suPAR level was found to be linked to a characteristic plasma proteome, associated with coagulation disorders and complement activation. Receiver operator characteristic curve analysis to predict mortality identified a cutoff value of suPAR at 1,996.809 pg/ml (odds ratio: 2.9286, 95% confidence interval 1.0427-8.2257). Lower-than-cutoff suPAR levels were associated with a differential expression of the immune transcriptome as well as favorable clinical outcomes, in terms of both survival benefit (hazard ratio: 0.3615, 95% confidence interval 0.1433-0.912) and faster disease remission in our patient cohort. Thus, we identified suPAR as a key pathogenic circulating molecule linking systemic hyperinflammation to the hypercoagulable state and stratifying clinical outcomes in severe COVID-19 patients with ARDS.

Keywords: ARDS; COVID-19; Plaur; myeloid cells; prognosis; proteomics; soluble uPAR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Coagulation Disorders / blood
  • Blood Coagulation Disorders / immunology
  • Blood Proteins / analysis
  • COVID-19 / blood*
  • COVID-19 / immunology
  • Cytokines / blood
  • Humans
  • Inflammation / blood
  • Inflammation / immunology
  • Middle Aged
  • Myeloid Cells / immunology
  • Proteome / analysis
  • Randomized Controlled Trials as Topic
  • Receptors, Urokinase Plasminogen Activator / blood*
  • Respiratory Distress Syndrome / blood
  • Respiratory Distress Syndrome / immunology
  • SARS-CoV-2*
  • Severity of Illness Index
  • Young Adult

Substances

  • Blood Proteins
  • Cytokines
  • PLAUR protein, human
  • Proteome
  • Receptors, Urokinase Plasminogen Activator